Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34⁺ cells
J. Clin. Invest. Laure A. Moutouh-de Parseval, et al. 118:248 doi:10.1172/JCI32322 [Go to this article.]

Figure 5
Pomalidomide and lenalidomide are more potent than HU and butyrate for inducing HbF expression in CD34-derived erythrocytes. (A) HbF expression was monitored by flow cytometry after 6 days of erythroid differentiation, with increasing concentration of pomalidomide, lenalidomide, HU, and butyrate. (B) Cell viability was monitored after 6 days by forward- and side-scattering intensity in dot plots. Results represent mean ± SEM (n = 3) and are representative of 3 independent experiments.